Dyne Therapeutics (DYN) announced the appointment of Vikram Karnani to its Board of Directors. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current CEO of Collegium Pharmaceutical (COLL)
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target lowered to $36 from $38 at Evercore ISI
- Dyne Therapeutics price target raised to $39 from $36 at Stifel
- Dyne Therapeutics Announces Upsized Public Offering
- Amazon initiated, GE Vernova upgraded: Wall Street’s top analyst calls
- Oppenheimer upgrades Dyne Therapeutics to Outperform, raises target to $40